Financial Statements

Ligand Pharmaceuticals Incorporated (LGND)


-4.85 (-5.44%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) 449392400-229-
Net Income -557-3629-
Stock Dividends -43815-23-229
Dividend Paid -5-15-3-3-
Retained Earnings 0449392400-229

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 3323105-
Annual Depreciation 01917817
Capital Expenditure -18-9-4-3-12
Net PPE 153323105

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -306306785735
New Purchases -1,434-2,357-423-181-51
Intangible and Goodwill 306306785735448

Ligand Pharmaceuticals Incorporated income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Ligand Pharmaceuticals Incorporated FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.